

1 **Effectiveness of Four Vaccines in Preventing SARS-CoV-2 Infection in Kazakhstan**

2

3 **Authors and academic degrees:**

4 Dilyara Nabirova,^{1,2} Roberta Horth,^{1,2} Manar Smagul,³ Gaukhar Nukenova,³ Aizhan

5 Yesmagambetova⁴, Daniel Singer^{1,2}, Alden Henderson⁵, Alexey Tsoy⁴

6

7 **Affiliations:**

8 1. **U.S. Centers for Disease Control and Prevention, Central Asia Regional Office**, Almaty,

9 Kazakhstan; hny5@cdc.gov; ORCID ID 0000-0002-0314-2202; hxw5@cdc.gov, ORCID ID

10 0000-0003-1810-2542; dps4@cdc.gov;

11 2. **Asfendiyarov Kazakh National Medical University**, Almaty, Kazakhstan,

12 a. Scientific and practical center of sanitary-epidemiological examination and

13 monitoring, branch of the National Center for Public Health, Almaty, Kazakhstan;

14 gnukenova@mail.ru; manar.smagul@gmail.com,

15 3. **Ministry of Healthcare**, Nur-Sultan, Kazakhstan; yesmagambetovaa@gmail.com;

16 alex_tsoy@mail.ru

17 4. **U.S. Centers for Disease Control and Prevention**, Atlanta, USA; akh0@cdc.gov

18

19 **Correspondence:** Dr. Dilyara Nabirova, U.S. Centers for Disease Control and

20 Prevention, Central Asia, Almaty, Kazakhstan; E-mail: hny5@cdc.gov

21 **Disclaimer:** The findings and conclusions in this report are those of the author(s) and do not

22 necessarily represent the official position of the U.S. Centers for Disease Control and Prevention

23 **Word count:** 3473

24 **ABSTRACT (250/250)**

25

26 **BACKGROUND**

27 In February 2021 Kazakhstan began offering COVID-19 vaccines to adults. Breakthrough
28 SARS-CoV-2 infections raised concerns about real-world vaccine effectiveness. We aimed to
29 evaluate effectiveness of four vaccines against SARS-CoV-2 infection.

30

31 **METHODS**

32 We conducted a retrospective cohort analysis among adults in Almaty using aggregated
33 vaccination data and individual-level breakthrough COVID-19 cases (≥ 14 days from 2nd dose)
34 using national surveillance data. We ran time-adjusted Cox-proportional-hazards model with
35 sensitivity analysis accounting for varying entry into vaccinated cohort to assess vaccine
36 effectiveness for each vaccine (measured as 1-adjusted hazard ratios) using the unvaccinated
37 population as reference (N=565,390). We separately calculated daily cumulative hazards for
38 COVID-19 breakthrough among vaccinated persons by age and vaccine month.

39

40 **RESULTS**

41 From February 22 to Sept 1, 2021 in Almaty, 747,558 (57%) adults were fully vaccinated
42 (received 2 doses) and 108,324 COVID-19 cases (11,472 breakthrough) were registered. Vaccine
43 effectiveness against infection was 78% (sensitivity estimates: 74–82%) for QazVac, 77% (72–
44 81%) for Sputnik V, 71% (69–72%) for Hayat-Vax, and 69% (64–72%) for CoronaVac. Among
45 vaccinated persons, the 90-day follow-up cumulative hazard for breakthrough infection was
46 2.2%. Cumulative hazard was 2.9% among people aged ≥ 60 years versus 1.9% among persons
47 aged 18–39 years ($p < 0.001$), and 1.2% for people vaccinated in February–May versus 3.3% in
48 June–August ($p < 0.001$).

49

50 **CONCLUSION**

51 Our analysis demonstrates high effectiveness of COVID-19 vaccines against infection in Almaty
52 similar to other observational studies. Higher cumulative hazard of breakthrough among people
53 > 60 years of age and during variant surges warrants targeted booster vaccination campaigns.

54 **What is already known on this topic**

- 55 • Plenty of data are published on effectiveness of mRNA vaccines; however, these
56 vaccines were not widely available in many low- and middle-income countries in 2021.
- 57 • There are no real-world effectiveness studies on several vaccines available in the Central
58 Asia region, including QazVac vaccine, an inactivated vaccine developed by Kazakhstan.
- 59 • Understanding how these vaccines are performing outside of clinical trials is critical for
60 the COVID-19 response and lack of published data can contribute to vaccine hesitancy.

61

62 **What this study adds**

- 63 • Our study demonstrated that at the population-level the four vaccines against COVID-19
64 used in Kazakhstan were effective at preventing SARS-CoV-2 infection.
- 65 • Vaccination reduced the risk of infection by 76% and prevented over 100,000 cases of
66 SARS-CoV-2 infection in Almaty, the country's most populous city.
- 67 • This is also the first study that demonstrated high vaccine effectiveness in real-world
68 conditions of QazVac, developed in Kazakhstan.

69

70 **How this study might affect research, practice or policy**

- 71 • Policy makers in Kazakhstan and the Central Asia region need data on vaccines provided
72 in the region to update evidence-based vaccine guidelines for different populations.

73 **INTRODUCTION**

74 From March 2020 to December 17, 2021 in Kazakhstan, over one million people were diagnosed
75 with coronavirus disease 2019 (COVID-19); ~18,000 died.¹ Vaccines have become a key tool for
76 reducing COVID-19-associated morbidity and mortality and preventing transmission of SARS-
77 CoV-2. In February 2021, Kazakhstan began offering COVID-19 vaccines to adults aged 18
78 years and older. By December 9, 2021, 71% of adults (~eight million people) had received at
79 least two doses of vaccines, including Sputnik V (Gam-COVID-Vac, Gamaleya Research
80 Institute of Epidemiology and Microbiology, Russia), QazVac (QazCovid-in, Research Institute
81 for Biological Safety Problems, Kazakhstan), CoronaVac (Sinovac Biotech, China), Sinopharm
82 (BBIBP-CorV, Beijing Institute of Biological Products, China) and Hayat-Vax (BBIBP-CorV,
83 G42 Healthcare, United Arab Emirates).²

84

85 Of the five vaccines available in Kazakhstan, two (CoronaVac and Sinopharm) were listed for
86 emergency use globally by the World Health Organization (WHO) by end of 2021. The WHO
87 pre-qualifies and lists vaccines based on several guidelines³ including Good Manufacturing
88 Practice (GMP) and >50% vaccine efficacy in preventing SARS-CoV-2 outcomes in clinical
89 trials.^{4,5} Among the WHO listed vaccines, vaccine efficacy against symptomatic disease in
90 randomized-controlled trials was 51-84% for CoronaVac, 79% for Sinopharm, 63-76% for
91 AstraZeneca, and >90% for Moderna and Pfizer–BioNTech vaccines.^{4,5,6}

92

93 Although not listed by the WHO, Sputnik V and QazVac vaccines have received emergency use
94 authorization from the Kazakhstan Ministry of Health. They have shown interim efficacy of
95 >90% and safety in phase III and II clinical trials, respectively.⁷⁻¹⁰ Additionally, Sputnik V

96 demonstrated 79-86% effectiveness against infection and 85-93% effectiveness against COVID-
97 19 related death in a number of observational studies outside of clinical trials (real-world).^{11, 12}

98
99 Increasing breakthrough COVID-19 infections among vaccinated people raised concerns about
100 the real-world effectiveness of available vaccines. By the end of 2021, there were no real-world
101 effectiveness studies on the QazVac vaccine and limited data on the effectiveness of Sputnik V.
102 Understanding how vaccines are performing outside of clinical trials is important for healthcare
103 system preparedness and mitigation strategies. Policy makers in Kazakhstan needed data to
104 create evidence-based vaccine guidelines, including policies for booster vaccine doses for
105 different populations. We aimed to estimate daily hazard of breakthrough SARS-CoV-2 infection
106 among vaccinated people in Almaty, to identify groups at higher risk for breakthrough infection,
107 and to evaluate the overall effectiveness of four vaccines against infection.

108

109 **METHODS**

110 **Study design**

111 We conducted a retrospective, observational population-based cohort study of the vaccine
112 effectiveness of four different vaccines against SARS-CoV-2 infection among adults 18 years or
113 older in Almaty, Kazakhstan. Almaty is the economic capital and largest city of Kazakhstan with
114 an adult population of 1,313,040 (~10% of the national adult population).

115 **Key definitions**

116 A breakthrough COVID-19 infection was defined as having confirmed or probable COVID-19,
117 including people with asymptomatic disease, ≥ 14 days after receiving the 2nd dose of a COVID-
118 19 vaccine.

119
120 A confirmed COVID-19 case was defined as the detection of SARS-CoV-2 ribonucleic acid
121 (RNA) in a respiratory specimen collected from a person aged ≥ 18 years, including those with
122 asymptomatic disease.

123
124 A probable COVID-19 case was a patient who met clinical criteria (chest imaging suggesting
125 COVID-19, anosmia, ageusia in the absence of any other identified cause), did not have a
126 positive SARS-CoV-2 PCR test, and was a contact of a probable or confirmed case or linked to a
127 COVID-19 cluster.

128
129 Fully vaccinated was defined as having received two COVID-19 vaccine doses (there were no
130 single dose COVID-19 vaccines offered in Kazakhstan). Unvaccinated was defined as never
131 having received any COVID-19 vaccine. Partial vaccination was having received only one
132 vaccine dose. People who received only one dose were excluded from analysis.

133
134 We classified people into four groups. People who were:

- 135 (1) unvaccinated (never received any COVID-19 vaccine) and diagnosed with COVID-19,
136 (2) unvaccinated (never received any COVID-19 vaccine) and not diagnosed with COVID-19,
137 (3) fully vaccinated (two doses) and diagnosed with breakthrough COVID-19, and

138 (4) fully vaccinated (two doses) and not diagnosed with breakthrough COVID-19.

139

140 **Study population**

141 Our analysis included Almaty residents ages 18 years and older. The following people were
142 excluded from analysis (Supplementary Figure 1):

- 143 • People that received only their first dose of vaccine and had a positive SARS-CoV-2 PCR
144 test <14 days after the first vaccine dose.¹³
- 145 • People whose records were inconsistent with national vaccination guidelines (e.g. second
146 dose was <7 days of the first dose or they had COVID-19 diagnosis <25 days before their
147 second dose).
- 148 • People who received the Sinopharm vaccine (only 20 people).
- 149 • People who had SARS-CoV-2 PCR positive result <14 days after their second dose. This last
150 group was included in sensitivity analysis.

151 Data on history of COVID-19 prior to the study period was not available; therefore, we do
152 not exclude based on prior disease.

153

154 **Data sources**

155 Individual-level data on COVID-19 cases among anyone who had ever received a COVID-19
156 vaccine were provided by the Emergency Operational Center (EOC) of the National Center of
157 Public Health of the Ministry of Health in Kazakhstan from February 1 to September 1, 2021.

158 Data on all COVID-19 cases from testing centers, laboratories, hospitals, and healthcare
159 providers are collected by the EOC. This clinical record dataset included age, comorbidities,
160 dates of COVID-19 vaccination, vaccine name, date of SARS-CoV-2 PCR test result or

161 diagnosis, hospitalization, death, and disease severity. Disease severity was based on the WHO
162 Scale adapted by the Kazakhstan clinical protocol of diagnosis and treatment. People with
163 critical disease had acute respiratory distress, those with severe disease had severe pneumonia,
164 those with moderate disease had pneumonia, and those with mild disease did not have
165 pneumonia. Data aggregated per day on SARS-CoV-2 polymerase chain reaction (PCR) testing,
166 which included the number of people testing positive per day for the same period, were also
167 provided.

168

169 Aggregated data on vaccination were received from the Salidat Kairbekova National Research
170 Center for Health Development of the Ministry of Health in Kazakhstan. Variables were
171 aggregated by date and included the number of people vaccinated per day per age group and
172 vaccine type.

173

174 **Statistical analysis**

175 Analyses were performed using R statistical software, version 4.0.3 (R Foundation for Statistical
176 Computing). We calculated and plotted attack rates for the vaccinated and unvaccinated
177 populations for each day of our analysis for each vaccine type. We fitted time-dependent Cox
178 proportional hazards regression models using the `coxph()` function of the survival package to
179 assess the time to COVID-19 diagnosis by vaccination status. Vaccine status was a time-
180 dependent covariate that changed when the person received their 1st dose and 14 days after their
181 2nd dose.

$$\lambda(t|Z(t)) = \lambda_0(t) \exp\{\beta OZ(t)\}$$

182 The hazard at time t depends on the value of covariates at time $Z(t)$. The regression effect of $Z(\cdot)$
183 is constant β over time. The adjusted hazard ratio was $\exp\{\beta 0Z(t)\}$. Adjusted vaccine
184 effectiveness, measured as $1 - \exp\{\beta 0Z(t)\}$, and adjusted for day and vaccine status, was
185 assessed for each of the 4 vaccines using the unvaccinated population as the reference group.

186
187 The time of entry into the model was set at February 1, 2021, when COVID-19 vaccines became
188 available in Almaty. The entire population of adults ≥ 18 years old in Almaty ($N=1,313,040$) was
189 classified into the unvaccinated group at-risk for COVID-19 group. People contributed person-
190 time to the unvaccinated population until they either received a COVID-19 diagnosis or a
191 COVID-19 vaccine. After people received their first vaccine, they did not contribute person-time
192 to either population (vaccinated or unvaccinated) from their first dose to 14 days after their
193 second dose after which they contributed person-time to the vaccinated population. We
194 performed sensitivity analysis by changing the dates at which people entered the vaccinated
195 population (at first dose, second dose, second dose + 7 days or second dose + 14 days) and the
196 dates of definition of a COVID-19 breakthrough case (after second dose, second dose + 7 days or
197 second dose + 14 days). We show sensitivity estimates throughout for our results to more
198 accurately express the uncertainty around estimates.

199
200 We separately calculated crude vaccine effectiveness for each vaccine using the following
201 formula:

crude VE

$$= \frac{(\text{Incidence proportion among unvaccinated} - \text{Incidence proportion among vaccinated})}{\text{Incidence proportion among unvaccinated}}$$

202

203 We also estimated the number of COVID-19 cases prevented by multiplying the number of
204 vaccinated people by the overall incidence among the unvaccinated population, and subtracting
205 the number of breakthrough cases.

206
207 Lastly, we conducted sub analysis on the vaccinated population, we calculated the cumulative
208 hazard percent of getting COVID-19 using survfit() and plotted Kaplan-Meyer cumulative
209 hazard curves using ggsurvplot() function and by vaccine name, age group, and month. The log-
210 rank test was used to test difference in hazard curves.

211

212 **RESULTS**

213 From February 22 to September 1, 2021 in Almaty, 747,558 residents aged ≥ 18 years were fully
214 vaccinated against COVID-19 with Sputnik-V (668,452), Hayat-Vax (42,437), CoronaVac
215 (22,181), or QazVac (14,488) and met inclusion criteria (supplement figure). During this time,
216 Almaty had 108,324 probable and confirmed COVID-19 cases among people ≥ 18 years old,
217 including 23,858 cases among people with at least one COVID-19 vaccination record
218 (supplement figure). Of these 11,472 were fully vaccinated and met criteria for breakthrough
219 SARS-CoV-2 infection.

220

221 Among fully vaccinated people with breakthrough SARS-CoV-2 infections (table 1), 24% were
222 ≥ 60 years old and 11% had a known comorbidity and presence of comorbidity was unknown for
223 72%. The median interval between vaccine doses was 21 days (range 8–166). The median
224 interval between second dose and breakthrough infection was 59 days (range 14–178). Disease

225 was classified as critically severe for 0.7% and severe for 6.8% of cases, and 29% were
 226 hospitalized. There were 120 deaths (1%).
 227 **Table 1** Characteristics of fully vaccinated people with SARS-CoV-2 breakthrough infection,
 228 Almaty, Kazakhstan, 2021

Characteristics	N=11,472	% or (range)
Sex		
Female	6,923	60.3
Male	4,549	39.7
Age, median (range) ^o	45	(range 18 to 96)
18-39 years	4,360	38.0
40-59 years	4,351	37.9
≥ 60 years	2,761	24.1
Had a comorbidity		
No	1,892	16.5
Yes	1,271	11.1
Unknown	8,309	72.4
Fully vaccinated		
Sputnik V	9,826	85.7
Hayat-Vax	955	8.3
QazVac	187	1.6
CoronaVac	504	4.4
COVID-19 waves in Kazakhstan		
February 1- June 30, 2021	402	3.5
July 1- 31, 2021	2,335	20.4
August 1- September 1, 2021	8,735	76.1
PCR-identified cases		
PCR -	560	4.9
PCR +	10,912	95.1
Interval between 1st and 2nd dose in days, median (range)	21	(range 8 to 166)
8-14 days	259	2.3
15-19 days	395	3.4
20-25 days	8,449	73.6
26-46 days	1,906	16.6
47-166 days	463	4.0
Days since fully vaccinated to disease onset	59	(range 14 to 178)
COVID-19 severity*		
Critical disease	78	0.7
Severe disease	776	6.8
Moderate disease	2,154	18.8
Mild disease	8,464	73.8
Hospitalized		
No	8,146	71.0
Yes	3,326	29.0
Number of hospitalizations**		
One hospitalization	3,285	98.8
Two hospitalizations	41	1.2
Length of hospitalization in days, median (range)**	9	(range 1 to 35)
Outcome		
Recovered or transferred	11,352	99.0
Died	120	1.0

* WHO Scale adapted by the Kazakhstan clinical protocol of diagnosis and treatment (Coronavirus infection COVID-19 in adults);**Subset of persons having been hospitalized

229 Vaccination began on February 1, 2021 for Sputnik, April 25 for QazVac, May 3 for Hayat-Vax
 230 and June 6 for CoronaVac. During the study period, the adjusted vaccine effectiveness for all
 231 four vaccines was 76% (low and high sensitivity percent range of 71.1–80.0%) (table 2).
 232 Adjusted vaccine effectiveness varied by vaccine and was 77.0% (71.4–80.8%) for Sputnik V,
 233 78.6% (74.2–82.0%) for QazVac, 71.2% (69.3–73.0%) for Hayat-Vax, and 69.5% (64.7–71.5%)
 234 for CoronaVac (p<0.001).

235

236 **Table 2.** Vaccine effectiveness against SARS-CoV-2 infection of four COVID-19 vaccines in
 237 Almaty, Kazakhstan, 2021

Category	N	% aVE	95% CI	Sensitivity analysis				% cVE	95% CI
				Low	95% CI	High	95% CI		
Vaccine status									
Vaccinated	747,558	76.4*	(75.9-76.9)	71.1	(70.5-71.6)	80.0	(79.6-80.4)	89.7	(89.5-89.9)
Not vaccinated	565,370	Ref						Ref	
Vaccine name									
QazVac	14,488	78.6*	(75.3-81.4)	74.2	(70.2-77.7)	82.0	(79.2-84.4)	85.8	(83.6-87.7)
Sputnik-V	668,452	77.0*	(76.5-77.5)	71.4	(70.8-72.1)	80.8	(80.4-81.2)	90.4	(90.2-90.6)
Hayat-Vax	42,437	71.2*	(69.3-73.0)	69.1	(67.1-71.0)	72.4	(70.6-74.1)	73.2	(71.4-74.8)
CoronaVac	22,181	69.5*	(66.7-72.0)	64.7	(61.5-67.7)	71.5	(68.9-73.9)	71.1	(68.5-73.5)
Not vaccinated	565,370	Ref						Ref	

238

239 *Time-dependent Cox-proportional hazards log-rank test P-value <0.001

240 aVE: adjusted vaccine effectiveness, adjusted for time and vaccine status

241 CI: Confidence Interval

242 Low: day of contribution of person-time to vaccinated population begins on day of 1st dose

243 High: day of contribution of person-time to vaccinated population begins 14 days after 2nd dose

244 cVE: crude vaccine effectiveness; persons partially vaccinated (n=7482) and those with a case registered

245 before February 22, 2021 (n=2018) were excluded from the unvaccinated reference group

246 For all vaccines, the attack rate for COVID-19 per 100,000 was consistently higher over the 7-
247 day moving average for unvaccinated persons than for vaccinated persons (figure 1). The 7-day
248 moving average of daily vaccine effectiveness for all four vaccines remained above the WHO
249 50% threshold for vaccine efficacy⁵, except for one-week dips for QazVac in June and for
250 CoronaVac and Hayat-Vax in August. Based on overall incidence in the study period,
251 vaccination with these four vaccines prevented 100,213 cases of SARS-CoV-2 breakthrough
252 infection in Almaty.

253

254 **Figure 1.** Cumulative vaccinated, vaccine effectiveness against SARS-CoV-2 infection, and
255 attack rates among vaccinated and unvaccinated populations by four COVID-19 vaccines in
256 Almaty, Kazakhstan, 2021

257

258 Among people who were fully vaccinated (n=747,558), the 90-day cumulative hazard of
259 developing a SARS-CoV-2 breakthrough infection was 2.2%, ranging from 2.0% for Sputnik V
260 to 3.5% for Hayat-Vax (table 3). The cumulative hazard was significantly different by age group.
261 For people 60 years old and older the cumulative hazard was double that of people 18–39 years
262 old at the 180-day (12.8% vs 5.0%, respectively) and 90-day follow-ups (2.9% vs 1.9%).

263 **Table 3.** Cumulative hazard of SARS-CoV-2 breakthrough infection among persons fully
 264 vaccinated by four COVID-19 vaccines, Almaty, Kazakhstan, 2021

Group	N	Cumulative Hazard Percent						Trend Line	P-value	
		Day	30	60	90	120	150			180
All vaccine	747 558		0.5%	1.2%	2.2%	3.9%	5.1%	6.7%		<0.001
Sputnik	668 452		0.4%	1.0%	2.0%	3.7%	4.9%	6.5%		
QazVac	14 488		0.5%	1.4%	2.5%	3.5%				
Hayat	42 437		0.4%	2.0%	3.5%					
CoronaVac	22 181		1.0%	2.6%						
Age										<0.001
18-39	387 024		0.4%	1.1%	1.9%	2.9%	3.8%	5.0%		
40-59	272 225		0.5%	1.2%	2.2%	3.9%	5.2%	6.8%		
60+	88 309		0.5%	1.4%	2.9%	5.9%	8.8%	12.8%		
Month										<0.001
Feb	1 171		0.1%	0.3%	0.8%	0.9%	1.3%	2.7%		
Mar	2 844		0.3%	0.5%	0.6%	1.0%	2.1%	3.8%		
Apr	53 371		0.1%	0.2%	0.7%	2.3%	3.6%			
May	147 046		0.1%	0.3%	1.3%	3.0%				
Jun	105 171		0.3%	1.5%	2.7%					
Jul	221 353		0.8%	2.0%						
Aug	208 821		0.6%							
Sep	7 781									

265
 266 This divergence in hazard by age group over follow-up time was observed across the four
 267 vaccines ($p < 0.001$) (figure 2). Cumulative hazard curves began to diverge by age at
 268 approximately 90 days postvaccination for Sputnik V, and at approximately 30 days
 269 postvaccination for other vaccines. Cumulative hazard is also significantly different by study
 270 period ($p < 0.001$) when comparing people who were vaccinated in March to May 2021 to those
 271 vaccinated in June to September 2021 (the period when the SARS-CoV-2 Delta variant was
 272 active in the region). However, in vaccine-specific analysis, this difference was only significant
 273 for QazVac and Sputnik V.

274 **Figure 2.** Cumulative hazard curves by age group and period of 2nd dose by vaccine type by 4
275 COVID-19 vaccines, Almaty, Kazakhstan, 2021

276

277 **DISCUSSION**

278 Our study demonstrated that at the population-level the four vaccines against COVID-19 used in
279 Kazakhstan were effective at preventing SARS-CoV-2 infection. Vaccination reduced the risk of
280 infection by 76% and prevented over 100,000 cases of SARS-CoV-2 infection in Almaty, the
281 country's most populous city. The vaccine effectiveness for all four vaccines exceeded the 50%
282 vaccine efficacy minimum threshold set by the WHO for approving vaccines. Vaccine
283 effectiveness also remained relatively stable over the period, despite a slight decrease observed
284 during the months when the SARS-CoV-2 Delta variant became the predominant circulating
285 strain worldwide.

286

287 QazVac had 79% vaccine effectiveness in our study, but accounted for only 2% of people
288 vaccinated. Vaccine effectiveness for QazVac in our analysis was similar to the vaccine efficacy
289 reported in phase III clinical trials (81%).¹⁰

290

291 The predominant vaccine given in Kazakhstan during the period of analysis was Sputnik V (89%
292 of vaccinated people) and our observed vaccine effectiveness of 73% compares to (79% and
293 86%) vaccine effectiveness from limited observational studies, but lower than 92% vaccine
294 efficacy estimate from phase III clinical trials. However, these clinical trials took place before
295 Delta became the predominant variant.^{8, 11, 12}

296

297 CoronaVac had the lowest vaccine effectiveness in our analysis, and the estimate fell within the
298 range of vaccine efficacy phase III trials (51% to 84%) in several countries.^{6, 14-17} It is also
299 consistent with vaccine effectiveness against symptomatic disease reported in a comparable
300 study from Chile (66%).¹⁸ Vaccine effectiveness for Hayat-Vax (71%) was also within the range
301 of vaccine effectiveness reported in similar studies in Hungary and Peru (69% and 50%,
302 respectively)^{11, 19} and vaccine efficacy reported by Sinopharm (the same BBIBP-CorV vaccine
303 manufactured in China) for phase III clinical trials (79%).^{6, 20}

304
305 Although COVID-19 vaccines used globally are highly effective, people who are fully
306 vaccinated may experience breakthrough SARS-CoV-2 infections, especially when the incidence
307 is high, and the proportion of people vaccinated in a population is low. In Kazakhstan,
308 population vaccination began shortly before the Delta surge. As expected, breakthrough cases
309 occurred among vaccinated people, increasing as SARS-CoV-2 incidence increased in the
310 country. However, out of every 100 people fully vaccinated in Almaty during our study period
311 less than 2 had breakthrough infections. The low proportion of people getting breakthrough
312 COVID-19 in our study is within the range of that reported in other settings (<1 to 8%).^{21, 22} Not
313 only are vaccines effective for reducing infection, they are also highly effective at reducing
314 morbidity and mortality;^{23, 24} in our study, the majority of people with breakthrough infection
315 had mild disease.

316
317 Proportion of breakthrough infections increased over time, especially among people >60 years of
318 age and during the SARS-CoV-2 Delta variant surge.^{6, 25} This increase was most notable among
319 people vaccinated with Sputnik V because it had the longest period of follow-up, but the follow-

320 up period was limited to <90 days for 2 of the 4 vaccines studied. We cannot distinguish whether
321 the declining effectiveness was attributable to waning immunity or emergence of new SARS-
322 CoV-2 variants. However, waning immunity has been demonstrated in several studies that found
323 reduced neutralizing antibodies over time in people vaccinated against COVID-19 with
324 CoronaVac, Sputnik V, and BNT162b2 (Hayat-Vax) vaccines, and others.^{6, 26} Our results align
325 with Kazakhstan's recommendation to offer booster vaccinations for older populations, and with
326 CDC and WHO recommendations for booster doses for all vaccinated adults.

327
328 During data cleaning, we found 1,204 cases where the dates of vaccination and disease onset
329 conflicted with national vaccine administration directives. While some errors could be recording
330 problems, many are likely falsified certification of vaccinations (fake vaccine passports). Fake
331 vaccine passports are known problems in the Central Asia Region and in Kazakhstan.²⁷⁻²⁹ The
332 fake vaccine passports undermine efforts to mitigate COVID-19. Falsification occurs in part
333 because authorities have required COVID-19 vaccinations for certain populations, but vaccine
334 confidence is low. Data on real-world effectiveness of vaccines may help address low vaccine
335 confidence.

336
337 Vaccine confidence can also be boosted through increased global recognition of efficacious
338 vaccines. Despite trials showing high vaccine efficacy and studies showing real-world vaccine
339 effectiveness in several countries, only 1 of the 4 vaccines in our study, CoronaVac, is accepted
340 as proof of vaccination in several countries. The other vaccines, 2 of which have been used
341 widely globally, have not completed submission of all requirements for WHO approval.

342

343 **Strengths and limitations**

344 This is the first study from Kazakhstan reporting the real-world effectiveness of four available
345 vaccines based on the retrospective cohort analysis in the largest city of the country using
346 aggregated vaccination data and individual-level breakthrough case national surveillance data.
347 Three of these studied vaccines are not accepted for international travel by most governments
348 worldwide. This is also the first study to estimate vaccine effectiveness for QazVac, an
349 inactivated vaccine developed in Kazakhstan, in real-world conditions. Our results are relevant
350 for planning and scale-up of COVID-19 vaccination efforts in the region.

351
352 Our study is subject to at least five important limitations. First, we could not assess vaccine
353 effectiveness against severe disease, hospitalization, and death because individual level data on
354 unvaccinated people who died or were hospitalized were not available for our analysis. Second,
355 we were not able to adjust for potential confounders, such as age or underlying medical
356 conditions, because this data was not available. Our analysis is likely not biased by age because
357 the population proportion ages 60 years and older among vaccinated people (12%) approximates
358 that proportion in the general adult population.³⁰ Additionally, the analysis captures 57% of the
359 vaccinated population. Third, when only people with symptoms of COVID-19 test, vaccine
360 effectiveness may be overestimated. However, testing was widely available in Almaty during the
361 study period, with no documented shortages. There were no changes in testing policy over this
362 time, and proof of COVID-19 negative test results were required for participation in several
363 activities. Also, the seven-day moving average of COVID-19 tests tracked the epidemic curve.
364 Fourth, individual data was available only for COVID-19 cases among vaccinated people and
365 cases among unvaccinated people were aggregate. We could not remove potential duplicates

366 from aggregated COVID-19 case data. Fifth, though we attempted to remove fake vaccine
367 passports from the analysis, we cannot ascertain status of all vaccine records and people who
368 were not vaccinated may have been included in the vaccinated population.

369

370 **CONCLUSION**

371 We found that 4 vaccines used in Almaty were highly effective against SARS-CoV-2 infection.
372 Our results may help increase vaccine confidence in Kazakhstan and the region. Scale-up of
373 efforts to fully vaccinate all eligible unvaccinated persons and to providers booster doses to
374 persons already fully vaccinated, people >60 years of age and during variant surges, will help
375 reduce SARS-CoV-2 incidence.

376

377 **Contributors:** DN, RH, MS, GN, AY, DS, AH and AT conceived and designed the study. DN,
378 RH, and GN did the statistical analysis. MS, GN, AY, and AT were responsible for data curation.
379 DN, RH, AH, and DS searched the existing literature. DN, RH, and AH wrote the original draft
380 of the manuscript and all authors reviewed and edited the manuscript for intellectual content. DN
381 and RH prepared data visualization. AY, DS, and AT were responsible for study administration.
382 The corresponding author confirms that all listed authors meet authorship criteria and that no
383 others meeting the criteria have been omitted.

384

385 **Funding:** None.

386

387 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
388 www.icmje.org/coi_disclosure.pdf and declare no conflict of interest; no support from any
389 organization for the submitted work; no financial relationships with any organizations that might

390 have an interest in the submitted work in the previous three years; no other relationships or
391 activities that could appear to have influenced the submitted work.

392

393 **Ethical approval:** The study was deemed non-research public health activity by the MoH of
394 Kazakhstan and the institutional review board of CDC and conducted in accordance with CDC
395 policy (project ID 0900f3eb81e4b259)

396

397 **Data sharing:** The authors cannot share individual level data due to the national data protection
398 regulations. Deidentified data might be made available for authorized researchers after
399 application to the Ministry of Healthcare of the Republic of Kazakhstan.

400 The authors confirm that the manuscript is an honest, accurate, and transparent account of the
401 investigation being reported; and that no important aspects of the study have been omitted.

402

403 Dissemination to participants and related patient and public communities: The Ministry of
404 Healthcare of the Republic of Kazakhstan and the authors will disseminate the study findings
405 through press releases, a website (<https://rk-ncph.kz/ru/>), and through social media.

406

407 **Provenance and peer review:** Not commissioned; externally peer reviewed.

408

409 **References**

- 410 1. World Health Organization Health Emergency Dashboard. Kazakhstan Situation. Data as received
411 by WHO from national authorities by 5:51pm CET, 17 December 2021. Available at
412 <https://covid19.who.int/region/euro/country/kz>.
- 413 2. Over 8 million Kazakhstanis fully vaccinated against coronavirus. November 30, 2021. Available
414 at [https://primeminister.kz/en/news/bolee-8-mln-kazahstancsev-polnostyu-vakcinirovalis-ot-](https://primeminister.kz/en/news/bolee-8-mln-kazahstancsev-polnostyu-vakcinirovalis-ot-koronavirusa-30103645)
415 [koronavirusa-30103645](https://primeminister.kz/en/news/bolee-8-mln-kazahstancsev-polnostyu-vakcinirovalis-ot-koronavirusa-30103645).

- 416 3. Zahid MN, Moosa MS, Perna S, Buti EB. A review on COVID-19 vaccines: stages of clinical trials,
417 mode of actions and efficacy. Arab Journal of Basic and Applied Sciences. 2021 2021/01/01;28(1):225-
418 33.
- 419 4. World Health Organization. Vaccine efficacy, effectiveness and protection. 14 July 2021.
420 Available at [https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-](https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection)
421 [protection](https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection).
- 422 5. World Health Organization. Considerations for evaluations of COVID-19 vaccines. Points to
423 consider for manufacturers of COVID-19 vaccines. Version 23 September 2020. Available at
424 [https://www.who.int/medicines/regulation/prequalification/prequal-](https://www.who.int/medicines/regulation/prequalification/prequal-vaccines/WHO_Evaluation_Covid_Vaccine.pdf)
425 [vaccines/WHO Evaluation Covid Vaccine.pdf](https://www.who.int/medicines/regulation/prequalification/prequal-vaccines/WHO_Evaluation_Covid_Vaccine.pdf).
- 426 6. Mallapaty S. China's COVID vaccines have been crucial - now immunity is waning. Nature. 2021
427 Oct;598(7881):398-9. PubMed PMID: 34650240. eng.
- 428 7. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021
429 Feb 20;397(10275):642-3. PubMed PMID: 33545098. Pubmed Central PMCID: PMC7906719. Epub
430 2021/02/06.
- 431 8. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al.
432 Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an
433 interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671-
434 81. PubMed PMID: 33545094. Pubmed Central PMCID: PMC7852454. Epub 2021/02/06.
- 435 9. Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, et al. Safety
436 and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy
437 adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2
438 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine. 2021 2021/09/01;39:101078.
- 439 10. Khairullin, Berik and Zakarya, Kunsulu and Orynbayev, Mukhit and Abduraimov, Yergali and
440 Kassenov, Markhabat and Sarsenbayeva, Gulbanu and Sultankulova, Kulyaisan and Cherviyakova, Olga
441 and Myrzhakhmetova, Balzhan and Nakhanov, Aziz and Nurpeisova, Ainur and Zhugunissov, Kuandyk
442 and Assanzhanova, Nurika and Nurabayev, Sergazy and Kerimbayev, Aslan and Ershebulov, Zakir and
443 Burashev, Yerbol and Kulmagambetov, Ilyas and Davlyatshin, Timur and Sergeeva, Maria and Buzitskaya,
444 Zhanna and Stukova, Marina and Kutumbetov, Lespek, Efficacy and Safety of an Inactivated Whole-
445 Virion Vaccine Against COVID-19, QazCovid-in®, In Healthy Adults: A Multicentre, Randomised, Single-
446 Blind, Placebo-Controlled Phase 3 Clinical Trial With a 6-Month Follow-Up. Available at SSRN:
447 <https://ssrn.com/abstract=4016484> or <http://dx.doi.org/10.2139/ssrn.4016484>.
- 448 11. Vokó Z, Kiss Z, Surján G, Surján O, Barcza Z, Pályi B, et al. Nationwide effectiveness of five SARS-
449 CoV-2 vaccines in Hungary - The HUN-VE study. Clinical Microbiology and Infection.
- 450 12. González S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Marín L, et al. Effectiveness of the first
451 component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections,
452 hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina.
453 EClinicalMedicine. 2021 Oct;40:101126. PubMed PMID: 34541480. Pubmed Central PMCID:
454 PMC8435263. Epub 2021/09/21. eng.
- 455 13. Jacobson KB, Pinsky BA, Montez Rath ME, Wang H, Miller JA, Skhiri M, et al. Post-Vaccination
456 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the
457 Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic
458 Medical Center. Clinical Infectious Diseases. 2021.
- 459 14. de Faria E, Guedes AR, Oliveira MS, de Godoy Moreira MV, Maia FL, dos Santos Barboza A, et al.
460 Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary
461 report. medRxiv. 2021:2021.04.12.21255308.
- 462 15. World Health Organization. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine. FOR
463 RECOMMENDATION BY THE STRATEGIC ADVISORY GROUP OF EXPERTS (SAGE) ON IMMUNIZATION.

464 April 29, 2021. Available at [https://cdn.who.int/media/docs/default-](https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf)
465 [source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf](https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf).

466 16. Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III,
467 observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of
468 SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.
469 Vaccine. 2021 Oct 22;39(44):6520-8. PubMed PMID: 34620531. Pubmed Central PMCID: PMC8461222.
470 Epub 20210924. eng.

471 17. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an
472 inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised,
473 placebo-controlled, phase 3 trial in Turkey. The Lancet. 2021;398(10296):213-22.

474 18. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an
475 Inactivated SARS-CoV-2 Vaccine in Chile. The New England journal of medicine. 2021 Sep 2;385(10):875-
476 84. PubMed PMID: 34233097. Pubmed Central PMCID: PMC8279092. Epub 20210707. eng.

477 19. Silvia-Valencia J, Soto-Becerra P, Escobar-Agreda S, Fernández-Navarro M, Moscoso-Porras M,
478 Solari L, et al. (22 July 2021). Efectividad de la vacuna BBIBP-CorV para prevenir infección y muerte en
479 personal de salud [Effectiveness of the BBIBP-CorV vaccine to prevent infection and death in health
480 personnel] (Technical report) (in Spanish). Tabla 4, figura 2: Ministry of Health of Peru.

481 20. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated
482 SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. Jama.
483 2021 Jul 6;326(1):35-45. PubMed PMID: 34037666. Pubmed Central PMCID: PMC8156175. eng.

484 21. CTV News. What do we know about breakthrough COVID-19 cases? Experts break down the
485 science. Agusyt 26, 2021. Available at [https://www.ctvnews.ca/health/coronavirus/what-do-we-know-](https://www.ctvnews.ca/health/coronavirus/what-do-we-know-about-breakthrough-covid-19-cases-experts-break-down-the-science-1.5561879)
486 [about-breakthrough-covid-19-cases-experts-break-down-the-science-1.5561879](https://www.ctvnews.ca/health/coronavirus/what-do-we-know-about-breakthrough-covid-19-cases-experts-break-down-the-science-1.5561879).

487 22. New York State Department of Health. COVID-19 Breakthrough Data. Current estimates of cases
488 and hospitalizations by vaccine status, and vaccine effectiveness. Available at
489 <https://coronavirus.health.ny.gov/covid-19-breakthrough-data>.

490 23. Team CC-VBCI. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States,
491 January 1-April 30, 2021. MMWR Morbidity and mortality weekly report. 2021 May 28;70(21):792-3.
492 PubMed PMID: 34043615. Pubmed Central PMCID: PMC8158893 Journal Editors form for disclosure of
493 potential conflicts of interest. No potential conflicts of interest were disclosed. Epub 2021/05/28.

494 24. Agrawal U, Katikireddi SV, McCowan C, Mulholland RH, Azcoaga-Lorenzo A, Amele S, et al.
495 COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in
496 257 million people in Scotland (EAVE II): a prospective cohort study. The Lancet Respiratory
497 Medicine. 2021;9(12):1439-49.

498 25. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral
499 Response to BNT162b2 Covid-19 Vaccine over 6 Months. New Engl J Med. 2021;385(24):e84.

500 26. Lapa D, Grousova D, Matusali G, Meschi S, Colavita F, Bettini A, et al. Retention of Neutralizing
501 response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals. medRxiv.
502 2022:2022.01.15.22269335.

503 27. Kazakhstan is awash in fake vaccination passports. July 24th 2021. Available at
504 <https://www.economist.com/asia/2021/07/24/kazakhstan-is-awash-in-fake-vaccination-passports>.


505 28. Jonathan Greig, Staff Writer, Price for fake COVID-19 vaccine cards and passports drops to \$100:
506 report. ZDNet Security. Available at [https://www.zdnet.com/article/price-for-fake-covid-19-vaccine-](https://www.zdnet.com/article/price-for-fake-covid-19-vaccine-cards-and-passports-drops-to-100-report/)
507 [cards-and-passports-drops-to-100-report/](https://www.zdnet.com/article/price-for-fake-covid-19-vaccine-cards-and-passports-drops-to-100-report/).

508 29. Belovolchenko Hanna, Coronavirus Vaccines and Covid Passports Are Being Sold on the Dark
509 Web: Zaborona reports on cost and availability in Ukraine. Available at
510 [https://zaborona.com/en/coronavirus-vaccines-and-covid-passports-are-being-sold-on-the-dark-web-](https://zaborona.com/en/coronavirus-vaccines-and-covid-passports-are-being-sold-on-the-dark-web-zaborona-reports-on-cost-and-availability-in-ukraine/)
511 [zaborona-reports-on-cost-and-availability-in-ukraine/](https://zaborona.com/en/coronavirus-vaccines-and-covid-passports-are-being-sold-on-the-dark-web-zaborona-reports-on-cost-and-availability-in-ukraine/).


512 30. World Bank staff estimates based on age/sex distributions of United Nations Population
513 Division's World Population Prospects: 2019 Revision. Population ages 65 and above (% of total
514 population) - Kazakhstan. Available at
515 <https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=KZ>.

Figure 1. Cumulative vaccinated, vaccine effectiveness against SARS-CoV-2 infection, and attack rates among vaccinated and unvaccinated populations by 4 COVID-19 vaccines in Almaty, Kazakhstan, 2021

A – COVID-19 testing count, vaccinated population count, vaccine effectiveness (VE) and attack rates (AR)



B – Vaccinated population count, vaccine effectiveness (VE) and attack rates (AR) per vaccine



PP: Percent positive rolling 7-day average

VE: Vaccine effectiveness

SE: Low and high sensitivity estimates

AR: Attack rates per 100,000 people

N: The cumulative count of people vaccinated

Points represent the daily values and lines the moving 7-day averages.

Dotted line is at 50% vaccine effectiveness

Orange is the unvaccinated population and blue the vaccinated population

Figure 2. Cumulative hazard curves by age group and days since 2nd dose by vaccine type by 4 COVID-19 vaccines, Almaty, Kazakhstan, 2021

